25
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Clinical Pharmacokinetics of Amonafide (NSC 308847) in 62 Patients

, , , , , , , , , , & show all
Pages 320-327 | Published online: 11 Jun 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Steven L Allen & Ante S Lundberg. (2011) Amonafide: a potential role in treating acute myeloid leukemia. Expert Opinion on Investigational Drugs 20:7, pages 995-1003.
Read now

Articles from other publishers (4)

Bingliang Fang, Reza J Mehran, John V Heymach & Stephen G Swisher. (2015) Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer 34:3.
Crossref
John T. Norton, Mark A. Witschi, Lynn Luong, Akane Kawamura, Supurna Ghosh, M. Sharon Stack, Edith Sim, Michael J. Avram, Daniel H. Appella & Sui Huang. (2008) Synthesis and anticancer activities of 6-amino amonafide derivatives. Anti-Cancer Drugs 19:1, pages 23-36.
Crossref
Victoria J. Findlay. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference 1 5 .
Chun-Lin Chen, Kami K Thoen & Fatih M Uckun. (2001) High-performance liquid chromatographic methods for the determination of topoisomerase II inhibitors. Journal of Chromatography B: Biomedical Sciences and Applications 764:1-2, pages 81-119.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.